ADMA Biologics, Inc. — Form 10-Q Summary
Business context and reporting period
ADMA is a late-stage biopharmaceutical company developing plasma-based biologics for immune-compromised patients. Its lead candidate, RI-002, was in a pivotal Phase III study for primary immunodeficiency disease. The company also operates an FDA-licensed and German-certified plasma collection center in Georgia, which generated substantially all reported revenue. The filing covers the unaudited three and nine months ended September 30, 2013, compared with the corresponding 2012 periods.
Financial performance and position
| Metric | Three months ended September 30 | Nine months ended September 30 |
|---|---|---|
| Total revenue | $1.107 million, versus $0.360 million | $2.644 million, versus $0.595 million |
| Gross profit | $0.381 million; approximately 34.4% gross margin | $0.902 million; approximately 34.1% gross margin |
| Operating loss | $2.531 million, versus $3.249 million | $10.524 million, versus $5.669 million |
| Net loss | $2.689 million, or $0.46 per share | $10.826 million, or $1.84 per share |
| Cash used in operating activities | Not separately provided | $7.927 million, versus $5.097 million |
- Revenue consisted primarily of plasma sales: $1.088 million in the quarter and $2.618 million year to date. License revenue was $18,889 in the quarter and $25,185 year to date. No revenue had been generated from the therapeutics business.
- At September 30, 2013, cash and cash equivalents were $5.380 million, down from $12.536 million at December 31, 2012. Working capital was $4.627 million.
- Total liabilities were $9.438 million, compared with $6.132 million at year-end 2012. Notes payable, net of debt discount, were $4.841 million; the underlying Hercules principal was $5.0 million.
- Stockholders’ equity declined to a deficiency of $0.736 million from equity of $9.424 million at December 31, 2012, primarily because of the $10.826 million year-to-date net loss.
Material changes versus the prior comparable period
- Quarterly revenue increased by more than 100%, primarily because of higher plasma sales from increased donor recruitment, advertising, promotions and additional collection equipment.
- Nine-month revenue increased by $2.049 million, but the benefit was more than offset by increased development spending.
- Nine-month research and development expense increased to $6.347 million from $2.201 million, driven by Phase III manufacturing, clinical, testing, regulatory and related personnel costs.
- Nine-month general and administrative expense increased to $3.367 million from $2.446 million, including an $805,818 write-off of deferred financing fees and higher staffing and stock-based compensation costs.
- Nine-month interest expense increased to $450,574 from $14,241 following the Hercules debt financing. The company also recorded a $60,568 favorable change in the fair value of the related warrant liability.
- Deferred revenue of $1.7 million was recorded in the second quarter for research and development services under the Biotest license agreement and is being recognized over the service period.
Guidance, outlook, risks and unusual items
- Management expected preliminary Phase III RI-002 data in the fourth quarter of 2014, a potential Biologics License Application filing in the first half of 2015, and potential first commercial sales as early as the first half of 2016. These milestones were subject to clinical, manufacturing and regulatory uncertainty.
- The company completed enrollment of 58 patients at nine U.S. treatment centers in its pivotal Phase III trial. FDA approval was not assured, and additional trials could be required.
- On October 22, 2013, after the reporting period, the company completed an IPO of 3,352,941 shares at $8.50 per share and received net proceeds of approximately $26.5 million. Restricted cash of $452,004 was also released on October 1, 2013.
- Management believed the September 30 cash balance plus IPO proceeds would fund operations into the first half of 2016, but stated that additional financing could be needed sooner if operating assumptions change.
- The company has incurred cumulative losses of $47.9 million and continued to report negative operating cash flow. Failure to obtain additional capital could require delaying or reducing clinical, research and commercialization activities or could threaten continuation of operations.
- Revenue was substantially dependent on one customer, and future revenue from RI-002 depended on successful development, regulatory approval, manufacturing and commercialization.
- The Hercules loan is secured by company assets, bears interest at 8.5% as of September 30, 2013, requires principal repayment beginning no later than May 1, 2014, and matures in June 2016. It includes financial and operating covenants, prepayment charges and customary events of default.
- The IPO terminated the down-round protection feature of the Hercules warrant; the warrant liability was expected to be reclassified to additional paid-in capital in the fourth quarter of 2013.
- Management reported no material legal claims and concluded that disclosure controls and procedures were effective as of September 30, 2013.
Important facts for investors to verify
- Whether RI-002 met Phase III efficacy and safety endpoints and whether the FDA accepted and approved the planned BLA.
- The company’s actual cash runway relative to the projected first-half-2016 funding date and any subsequent financing requirements.
- Plasma collection volumes, customer concentration and sustainability of plasma revenue and gross margins.
- Terms, repayment status and covenant compliance for the Hercules debt and related warrant accounting.
- Recognition timing and remaining balance of the $1.7 million deferred revenue obligation under the Biotest agreement.
- The effect of the October 2013 IPO on dilution, capitalization and the company’s post-period liquidity.